Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001415889-25-024369
Filing Date
2025-09-12
Accepted
2025-09-12 16:15:25
Documents
1
Period of Report
2025-09-10

Document Format Files

Seq Description Document Type Size
1 form4-09122025_040917.html 4  
1 form4-09122025_040917.xml 4 7766
  Complete submission text file 0001415889-25-024369.txt   9250
Mailing Address C/O AVEXIS, INC., 2275 HALF DAY ROAD SUITE 160 BANNOCKBURN IL 60015
Business Address
Nagendran Sukumar (Reporting) CIK: 0001665124 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39536 | Film No.: 251311680

Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Issuer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)